Onkológia 6/2019
Locoregional treatment of hepatocellular carcinoma
The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last 20 years. Patient survival is determined by the stage of the disease at the time of diagnosis and subsequent selection and availability of optimal therapies. Treatment of hepatocellular carcinoma is dependent on the stage of disease and severity of the underlying liver disease. Therapeutic approaches for the treatment of HCC can be classified into three categories: potentially curative, palliative, and symptomatic. However, only 20% of patients receive curable treatment due to disease progression, size or unfavorable tumor localization, patient comorbidities, or shortage of donor livers (1, 2). The majority of HCC patients are subjected to palliative or symptomatic treatment. Radiofrequency ablation (RFA), is becoming an alternative for very early and early-stage disease. Transarterial chemoembolization (TACE) is the modality of choice for intermediatestage disease. In the advanced stage of the disease, radioembolization (TARE) is an alternative to systemic treatment.
Keywords: hepatocellular carcinoma, stage of disease, ablative methods, embolization methods
